



University of Warwick institutional repository: <http://go.warwick.ac.uk/wrap>

This paper is made available online in accordance with publisher policies. Please scroll down to view the document itself. Please refer to the repository record for this item and our policy information available from the repository home page for further information.

To see the final version of this paper please visit the publisher's website. Access to the published version may require a subscription.

Author(s): Duska J Sidjanin, Catherine A McCarty, Richard Patchett, Edward Smith, Russell A Wilke

Article Title: Pharmacogenetics of ophthalmic topical β -blockers

Year of publication: 2010

Link to published article: <http://dx.doi.org/10.2217/17410541.5.4.377>

Publisher statement: None



Published in final edited form as:

Per Med. 2008 ; 5(4): 377–385. doi:10.2217/17410541.5.4.377.

Pharmacogenetics of ophthalmic topical β -blockers

Duska J Sidjanin^{1,2,†}, Catherine A McCarty³, Richard Patchett³, Edward Smith², and Russell A Wilke^{2,3,4,5}

¹Medical College of Wisconsin, Department of Cell Biology, Neurobiology and Anatomy, Milwaukee, WI, USA, Tel.: +1 414 456 7810; Fax: +1 414 456 6516; E-mail: dsidjani@mcw.edu

²Medical College of Wisconsin, Human and Molecular Genetics Center, Milwaukee, WI, USA

³Marshfield Clinic Research Foundation, Marshfield, WI, USA

⁴Medical College of Wisconsin, Department of Pharmacology and Toxicology, Milwaukee, WI, USA

⁵Medical College of Wisconsin, Department of Medicine, Milwaukee, WI, USA

Abstract

Glaucoma is the second leading cause of blindness worldwide. The primary glaucoma risk factor is elevated intraocular pressure. Topical β -blockers are affordable and widely used to lower intraocular pressure. Genetic variability has been postulated to contribute to interpersonal differences in efficacy and safety of topical β -blockers. This review summarizes clinically significant polymorphisms that have been identified in the β -adrenergic receptors (*ADRB1*, *ADRB2* and *ADRB3*). The implications of polymorphisms in *CYP2D6* are also discussed. Although the candidate-gene approach has facilitated significant progress in our understanding of the genetic basis of glaucoma treatment response, most drug responses involve a large number of genes, each containing multiple polymorphisms. Genome-wide association studies may yield a more comprehensive set of polymorphisms associated with glaucoma outcomes. An understanding of the genetic mechanisms associated with variability in individual responses to topical β -blockers may advance individualized treatment at a lower cost.

Keywords

β -adrenergic receptor; β -blocker; *CYP2D6*; glaucoma; IOP; polymorphisms; timolol

Glaucoma

Glaucoma is a group of heterogeneous ocular diseases defined by a progressive loss of the retinal ganglion cells, excavation or cupping of the optic nerve head, visual-field defects and, ultimately, blindness. With 70 million people affected with various forms of glaucoma, it is the second leading cause of blindness worldwide [1]. The primary risk factors include elevated intraocular pressure (IOP), aging, race and family history. In the general US population, it has been estimated that glaucoma affects 1–1.5% of people aged over 40–65 years, and 2–7% of those aged over 65 years. Prevalence varies with ethnicity; for example, the percentage of African-Americans affected with glaucoma ranges from 1.5 to 3.6% for those aged 40–65 years, and from 4.6 to 9.8% in individuals aged over 65 years [2].

[†]Author for correspondence.

Although glaucoma is defined as a progressive optic neuropathy, it is associated with functional and structural impairments of the trabecular meshwork, optic nerve head and retinal ganglion cells (Figures 1 & 2). The ciliary body, positioned behind the iris, secretes aqueous humor that flows into the anterior chamber (Figure 2). The role of the aqueous humor is to nourish the avascular ocular tissues of the anterior segment: the posterior cornea, the trabecular meshwork and the lens. In addition, the aqueous humor collects metabolic byproducts and drains out into the trabecular meshwork at the periphery of the anterior chamber, called the anterior chamber angle (Figure 2). In total, 10% of the aqueous humor outflows from the anterior chamber through the ciliary body via uveoscleral outflow. The IOP is a measurement of the aqueous humor pressure inside the eye and ranges from 10 to 21 mmHg. Elevated IOP is the most common clinical risk factor associated with the onset and progression of glaucoma, and generally results from compromised drainage via the trabecular meshwork.

The broad clinical classifications of glaucoma are based on anatomical characteristics of the anterior chamber angle or the age of onset. Classifications as open-angle glaucoma and closed-angle glaucoma are based upon the status of the anterior chamber angle. Each category is then further divided into primary and secondary subtypes. Primary open-angle glaucoma (POAG) is the most common subset, representing over 70% of all cases of glaucoma [3], and is characterized by an open anterior chamber angle, elevated IOP and glaucomatous optic nerve changes. Although elevated IOP is a major risk factor for development of POAG, a great deal of investigation has recently focused on normal-tension glaucoma, where the progressive damage to the optic nerve occurs even with normal IOP [4]. In contrast to POAG, primary angle-closure glaucoma (PACG) refers to a condition where the anterior chamber angle is closed, resulting in elevated IOP and glaucomatous optic nerve changes; PACG is more common in Asian populations [5]. Primary congenital glaucoma is an inherited structural anomaly within the trabecular meshwork and the anterior chamber angle [6]. Secondary glaucoma is commonly associated with clinical syndromes such as Axenfeld–Rieger syndrome and Peters' anomaly [7]. Despite our ability to discriminate these glaucoma subtypes clinically, the pathophysiologic mechanisms underlying the onset and progression of most types of glaucoma remain unclear.

The molecular etiology of glaucoma, and the molecular mechanisms governing the disease's onset and progression, are vastly unknown. There is strong evidence that glaucoma has a genetic basis. To date, at least 14 candidate POAG loci have been identified [101]; however, causative alleles associated with glaucoma have been defined for only a few genes. Mutations in the myocilin gene were initially identified in families segregating juvenile-onset primary-angle glaucoma [8]. However, subsequent analysis of patients with POAG also identified myocilin mutations in approximately 3–5% of POAG patients [8-10]. Similarly, mutations in the optineurin [11] and *WDR36* genes [12] have also been demonstrated to lead to glaucoma, although the mechanism of action of these genes is not yet well understood. Mutations in *CYP11B1* have been associated with primary congenital glaucoma [6], whereas mutations in the *Pitx2*, *Foxc1* and *Pax6* genes have been identified in patients with Axenfeld–Rieger syndrome and Peters' anomaly [7]. Despite these observations, the genetic cause associated with glaucoma remains unknown in most clinical situations. A better understanding of the onset and progression of glaucoma is needed at the molecular level. Such an understanding would likely open the door to novel strategies for the management of this potentially debilitating disease.

Current glaucoma therapy

At present, there are no therapies available that prevent the development of glaucoma. Similarly, no therapies are available to reverse glaucoma-induced vision loss. However, a reduction of the IOP has been shown to protect against further damage to the optic nerve head

[13]. As such, early diagnosis and proper treatment allow most glaucoma patients to retain good visual function. Unfortunately, glaucoma is initially asymptomatic. There have been no studies to assess population screening for open-angle glaucoma as a means to prevent vision loss, and the US Preventive Services Task Force found insufficient evidence to recommend for or against routine glaucoma screening in primary-care practices [14]. Once diagnosed, drug efficacy is a pivotal concern, since treatment has the capability to slow and/or arrest the progression of the glaucoma-associated irreversible vision loss.

Current treatment of POAG, the most common form of glaucoma, as well as ocular hypertension, focuses on the reduction of IOP. Drugs are usually administered topically to lower IOP. If necessary, additional topical agents and/or systemic drugs can be added. Drug management of glaucoma commonly includes five classes of drugs: α -adrenergic agonists, β -adrenergic antagonists, cholinergic agonists, prostaglandin analogs and carbonic anhydrase inhibitors [5]. Table 1 summarizes the available glaucoma drug treatments. The two most commonly prescribed drug groups are prostaglandin analogs, such as latanoprost, and β -blockers, such as timolol maleate [15]. If drugs fail to reduce IOP, laser therapy (trabeculoplasty) is applied to the trabecular meshwork to increase aqueous outflow. In the event that the laser trabeculoplasty fails to control the IOP, surgical procedures are applied to create a new route for aqueous humor outflow [5].

In pediatric cases of primary or secondary congenital glaucoma, medical therapy often plays a supportive role to surgery [16]. In this context, topical β -blockers (first line) and topical carbonic anhydrase inhibitors (second line) are preferred [16]. Prostaglandin analogs have limited efficacy for lowering IOP in pediatric patients [17].

Efficacy & safety of β -blockers in glaucoma treatment

β -blockers are one of the most commonly prescribed groups of drugs in the USA [18]. They are prescribed for the treatment of a number of vascular (e.g., coronary artery disease) and non-vascular (e.g., glaucoma) diseases. In the treatment of glaucoma, when applied topically, nonselective β -blockers, such as timolol maleate, reduce IOP by 27–35% [19]. β -blockers reduce IOP by inhibition of aqueous humor production [20] and not by increasing aqueous humor outflow [21,22]. The population-based efficacy of timolol has been well documented in the treatment of glaucoma [19,23]. However, two recent studies reported that timolol was less effective in lowering IOP in black patients than in non-black patients [24,25]. Although the molecular mechanisms responsible for the lower efficacy of timolol in black patients remain unknown, it has recently been suggested that iris pigmentation and differential nonspecific binding of the drug may play a role [26]. Alternatively, polymorphisms in the drug target genes may be associated with variable clinical responses to timolol [26].

When β -blockers are topically administered, they can be absorbed through the conjunctival epithelium, lacrimal channels, nasal mucosa and GI tract into the systemic circulation [27]. As a result, topical β -blockers can induce systemic adverse drug reactions, including contraction of the bronchial smooth muscle, bronchospasm, respiratory failure and death. In addition, cardiac side effects include bradycardia, hypotension, decreased myocardial contractility, and heart failure [28-29]. Adverse ocular affects of topical β -blockers are minimal, but in some cases timolol was reported to cause hyperemia of the conjunctiva, burning, stinging or superficial punctate keratitis [30,31], and reduced tear flow [32].

Economic implications

Currently, in the USA, over 2 million people are affected with POAG. By 2010, that number is expected to grow to over 3 million [2]. In recent years, topical prostaglandins have become a common first-choice glaucoma therapy, partly owing to their relatively consistent clinical

efficacy, and partly owing to their lower frequency of adverse effects [19]. However, topical prostaglandin analogs are expensive, ranging from US\$0.90 to US\$1.25 per day [33]. The least expensive option for the medical therapy of glaucoma, generic timolol products, has been shown to cost between US\$0.38 and US\$0.50 per day [34]. In a study considering cost, efficacy and safety of ocular β -blockers, it was concluded that timolol maleate should be the formulary agent of choice because other agents have not shown an outstanding advantage for the cost difference [35]. Understanding the molecular mechanisms guiding variability in response to topical β -blockers will be critical for advancing a more personalized and less expensive approach to the treatment of glaucoma.

ADRB genes as pharmacodynamic candidates

The interindividual variability in IOP response to β -blockers is unclear. It has been well established that, for most therapeutics administered at standard doses, a substantial proportion of patients do not respond to drug treatment. While some patients respond only partially, others experience adverse drug reactions [36]. Genetic variability contributes a great deal to population-based differences in drug efficacy and safety [37]. The *ADRB1*, *ADRB2* and *ADRB3* adrenergic receptors are highly expressed in the eye [102], whereas *ADRB1* and *ADRB2* were specifically identified in the ciliary body, trabecular meshwork and optic nerve head [38]. Therefore, adrenergic receptors were proposed as pharmacodynamic candidate genes potentially associated with the interpersonal variability of IOP response to topical β -blockers.

Adrenergic receptors are members of the large superfamily of G-protein-coupled receptors. Epinephrine and norepinephrine are the primary endogenous agonists, but other endogenous catecholamines (e.g., dopamine) and a variety of exogenous ligands (e.g., isoproterenol) are also known to interact with these receptors. Historically, the adrenergic receptors have been subdivided into β_1 and β_2 subtypes, based upon their relative binding affinity for various catecholamines. In general, β_1 adrenergic receptors demonstrate highest affinity for norepinephrine, intermediate affinity for epinephrine and lowest affinity for isoproterenol, whereas β_2 adrenergic receptors demonstrate highest affinity for isoproterenol, intermediate affinity for epinephrine and lowest affinity for norepinephrine. Each subtype is then further subdivided according to known physiologic function (e.g., β_1 receptors activate intracellular pathways with both chronotropic and inotropic cardiac effects).

Molecular biological techniques have revealed that there are at least three distinct β -adrenergic receptors, encoded by three separate genes (*ARDB1*, *ARDB2* and *ADRB3*) located at different chromosomal loci (chromosomes 10q25.3, 5q33.1 and 8p12, respectively). *ADRB1* and *ADRB2* are single-exon genes; the former is ultimately translated into a 477 amino acid protein, and the latter into a 413 amino acid protein. *ARDB3* has two exons and encodes a 408 amino acid protein. All three *ADRB* genes have a similar structure, comprising seven transmembrane domains, an extracellular amino terminus and an intracellular carboxy terminus [39]. *ADRB1* and *ADRB2* are expressed in the heart, and polymorphisms in both genes have been linked to hypertension and cardiovascular disease. In addition, genetic variations in *ADRB2* have also been linked to obesity and metabolic diseases. *ADRB3* is predominantly expressed in adipose tissue and is involved in lipolysis and thermogenesis.

All known *ADRB* genes contain functionally relevant polymorphisms. Sequence evaluation of *ADRB1* specifically identified two polymorphisms, Ser49Gly [40] and Arg389Gly [41]. *In vitro* functional analysis of *ADRB1* polymorphisms revealed that Ser49Gly is associated with the agonist-promoted downregulation of receptor expression and altered glycosylation [42]. The Arg389Gly *ADRB1* polymorphism, located within the intracellular domain near the

seventh transmembrane span, is in a region important for receptor G-protein coupling and the subsequent agonist-stimulated adenylyl cyclase activation [41].

Like *ADRB1*, the sequence evaluation of the *ADRB2* gene also identified two polymorphisms, Arg16Gly and Gln27Glu [43]. *In vitro* functional analyses of *ADRB2* polymorphisms have revealed that Arg16Gly is associated with the agonist-promoted downregulation of receptor expression, whereas the Gln27Glu polymorphism is resistant to receptor downregulation [43]. Both *ADRB1* and *ADRB2* polymorphisms have been associated with altered receptor function in a variety of clinical settings, including patients with congestive heart failure [44-45], nocturnal asthma [46], hypertension [47] and acute coronary syndromes [48].

Recently, a single polymorphism in the *ADRB3* gene has been associated with body composition in at least three separate populations [49-51]. In all three contexts, effect size was small and detection required adjustment for environmental covariates (e.g., gender and/or sedentary versus active lifestyle). This SNP, T727C, encodes an amino acid substitution (Trp64Arg) in the first transmembrane-spanning region of *ADRB3*, near its N-terminus. In a series of 695 adult Chinese subjects, this *ADRB3* SNP was associated with weight and BMI in men but not in women [52]. A similar effect was observed in 295 adult Japanese men, but only when the data were adjusted for energy intake [51]. In a study of 643 American women (representing both European and African heritage), no association was observed between this *ADRB3* SNP and any obesity phenotypes (i.e., BMI, waist circumference and waist:hip ratio [50]). The reason for gender discrepancy remains unclear and requires further characterization, since emerging data indicate that gender may impact phenotype in the context of glaucoma treatment [52].

The role of adrenergic receptor polymorphisms in variability of IOP response to β -blockers has recently been investigated. In healthy subjects, the Arg389Gly polymorphism in *ADRB1* has been associated with a higher baseline IOP and a greater reduction in IOP following topical betaxolol therapy [53]. Although the Ser49Gly polymorphism in *ADRB1* does not predict IOP response, it has been associated with higher systolic and diastolic blood pressure following treatment with topical timolol in healthy subjects and glaucoma patients [54].

Recent data indicate that *ADRB2* polymorphisms also influence clinical outcomes related to topical β -blockers. Our group evaluated the medical records of more than 18,000 adult subjects participating in a large population-based biobank [55-56]. Topical β -blockers had been prescribed for over 300 of these subjects, and over 200 of them had sufficient IOP data for the conduct of a pharmacogenetic association study. Males were significantly more likely than females to have a 20% or greater drop in IOP ($p < 0.01$). After adjusting for gender (and for family history of glaucoma), subjects with a homozygous major allele (CC) genotype at the Gln27Glu coding SNP in *ADRB2* were significantly more likely to experience a 20% or greater decrease in IOP (OR: 2.41; 95% CI: 1.00–5.82) [55]. It is noteworthy that *ADRB2* is the predominant adrenoceptor subtype in the iris–ciliary body [38]. To date, polymorphisms in the *ADRB3* gene have not been associated with β -blocker variability in glaucoma therapeutic response or etiology of glaucoma.

Since *ADRB2* is the predominant adrenoceptor in the iris–ciliary body, polymorphisms in *ADRB2* have also been hypothesized to play a role in the development of glaucoma as a disease process (i.e., in both the onset and rate of progression). In a Japanese cohort, POAG carriers of the Gly16 allele showed an earlier onset of the disease, and carriers of the Glu27 allele showed a higher IOP at the time of diagnosis [57]. However, these findings failed to replicate in a Turkish cohort [58], and in two ancestral US populations [59]. All clinically relevant polymorphisms identified in *ADRB* genes are summarized in Table 2.

CYP2D6 gene as a pharmacokinetic candidate

In general, many β -blockers are metabolized by a highly polymorphic drug-metabolizing enzyme, CYP2D6. The gene encoding the CYP2D6 enzyme is located on chromosome 22 q13.2; it contains eight coding exons, and it encodes a 446 amino acid protein. A total of 122 SNPs and/or short insertion/deletion polymorphisms have been reported within the *CYP2D6* genomic locus in human populations, resulting in at least 70 unique *CYP2D6* haplotypes [103].

Phase I oxidation by CYP2D6 inactivates many drugs within the β -blocker class. However, nearly 10% of the general population have a measurable deficit in their ability to metabolize CYP2D6 substrates. Patients with two functional copies of the *CYP2D6* gene (e.g., *CYP2D6**1/*1 homozygotes or *CYP2D6**1/*2 heterozygotes) are often referred to as extensive metabolizers. Poor metabolizers have two copies of a null allele. Intermediate metabolizers have at least one copy of an allele with reduced enzymatic activity. Gene duplication also occurs (e.g., *2XN), and these subjects are often referred to as having an ultrarapid metabolizer phenotype.

Clinically, ultrarapid metabolizers (e.g., *CYP2D6**2XN) have been shown to have lower plasma concentrations of metoprolol than extensive metabolizers [60], and poor metabolizers (expression of several potential variant genotypic combinations introduced above) exhibit several-fold higher plasma concentrations of metoprolol than extensive metabolizers [61]. A decade ago, investigators showed that CYP2D6 poor metabolizers have higher circulating timolol levels and correspondingly lower heart rates following systemic absorption of topical timolol therapy [62]. Despite these observations, very few reports have directly addressed the impact of *CYP2D6* gene variants on the IOP-lowering efficacy of topical β -blockers.

Recently, it has been reported that CYP2D6 poor metabolizers demonstrate altered serum kinetics following administration of the aqueous formulation of timolol (0.5% aqueous timolol), but not for the hydrogel formulation (0.1% timolol hydrogel) [54]. These findings suggest that, in the absence of knowledge regarding a patient's *CYP2D6* genotype, it may be safer to prescribe the formulation (hydrogel) with the less variable kinetic profile. Further studies are needed to characterize the potential utility of prospective knowledge regarding *CYP2D6* genotype prior to initiating these drugs.

Conclusion & future perspective

It has been estimated that, worldwide, 60.5 million people will be affected with POAG and PACG by the year 2010, and this number will likely increase to 79.6 million people by the year 2020 [63]. The least expensive options for the medical therapy of glaucoma are topical β -blockers, such as timolol maleate. Results are emerging in support of *ADRB2* gene polymorphisms in predicting therapeutic response to topical β -blockers [56]. Future studies need to consider other polymorphisms in both pharmacodynamic and pharmacokinetic candidate genes, and the impact of variability in their gene products should be considered specifically within the context of their respective intracellular signaling pathways. Growing information regarding signal transduction networks activated by topical β -blockers (e.g., downstream effectors of *ADRB*), and expert knowledge regarding the absorption, distribution, metabolism and elimination of these drugs (e.g., biotransformation mechanisms beyond phase I oxidation by CYP2D6), will likely prove useful for informing the analysis of large datasets, as the pharmacogenetics community moves towards the scanning of whole genomes [64,65].

Executive summary

Glaucoma

- Glaucoma is the second leading cause of blindness worldwide.
- Elevated intraocular pressure (IOP) is the primary risk factor associated with glaucoma.

Current glaucoma therapy

- Topical β -blockers are widely used to lower IOP.

Efficacy & safety of β -blockers in glaucoma treatment

- Genetic variability contributes to population-based differences in drug efficacy and safety.

Economic implications

- Topical β -blockers are the least expensive option for treatment of glaucoma.

ADRB genes as pharmacodynamic candidates

- An *ADRB1* gene polymorphism has been associated with a higher baseline IOP and a greater reduction in IOP following topical betaxolol therapy.
- A recent study suggests that *ADRB2* gene polymorphisms may predict therapeutic response to topical β -blockers.

CYP2D6 gene as a pharmacokinetic candidate

- None of the *CYP2D6* polymorphisms have been found to be associated with interindividual variability in IOP response to β -blockers.

Conclusion & future perspective

- Additional genes and polymorphisms likely contribute to efficacy and safety of β -blockers in glaucoma treatment.
- Novel approaches, such as genome-wide association studies, will identify gene variants that are predictive of the individual drug efficacy and toxicity of β -blockers.
- Understanding the molecular mechanisms underlying variability in response to topical β -blockers will be critical for advancing a more personalized approach to glaucoma.

Acknowledgements

Financial & competing interests disclosure This work was funded, in part, by start-up funds from the Department of Ophthalmology at the Medical College of Wisconsin (DJS), and Glaucoma Research, American Health Assistance Foundation (CAM). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Bibliography

Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.

1. Resnikoff S, Pascolini D, Etya'ale D, et al. Global data on visual impairment in the year 2002. Bull World Health Organ 2002;82:844–851. [PubMed: 15640920]


2. Friedman DS, Wolfs C, O'Colmain BJ, et al. Eye Diseases Prevalence Research Group. Prevalence of open-angle glaucoma among adults in the United States. *Arch Ophthalmol* 2004;122:532–538. [PubMed: 15078671] • **Combines data from a number of population-based epidemiologic studies to calculate estimates of the number of individuals affected by glaucoma in the USA.**
3. Foster PJ. The epidemiology of primary angle closure and associated glaucomatous optic neuropathy. *Semin Ophthalmol* 2002;17:50–58. [PubMed: 15513457]
4. Sowka J. New thoughts on normal tension glaucoma. *Optometry* 2005;76:600–608. [PubMed: 16230276]
5. Alward WL. Medical management of glaucoma. *N Engl J Med* 1998;29:1298–1307. [PubMed: 9791148]
6. Stoilov I, Akarsu AN, Sarfarazi M. Identification of three different truncating mutations in cytochrome P4501B1 (*CYP1B1*) as the principal cause of primary congenital glaucoma (buphthalmos) in families linked to the *GLC3A* locus on chromosome 2p21. *Hum Mol Genet* 1997;6:641–647. [PubMed: 9097971]
7. Idrees F, Vaideanu D, Fraser SG, Sowden JC, Khaw PT. A review of anterior segment dysgeneses. *Surv Ophthalmol* 2006;51:213–231. [PubMed: 16644364]
8. Stone EM, Fingert JH, Alward WLM, et al. Identification of a gene that causes primary open angle glaucoma. *Science* 1997;275:668–670. [PubMed: 9005853]
9. Suzuki Y, Shirato S, Taniguchi F, Ohara K, Nishimaki K, Ohta S. Mutations in the *TIGR* gene in familial primary open-angle glaucoma in Japan. *Am J Hum Genet* 1997;61:1202–1204. [PubMed: 9345106]
10. Wiggs JL, Vollrath D. Molecular and clinical evaluation of a patient hemizygous for *TIGR/MYOC*. *Arch Ophthalmol* 2001;119:1674–1678. [PubMed: 11709019]
11. Rezaie T, Child A, Hitchings R, et al. Adult-onset primary open-angle glaucoma caused by mutations in optineurin. *Science* 2002;295:1077–1079. [PubMed: 11834836]
12. Monemi S, Spaeth G, DaSilva A, et al. Identification of a novel adult-onset primary open-angle glaucoma (POAG) gene on 5q22.1. *Hum Mol Genet* 2005;14:725–733. [PubMed: 15677485]
13. Schulzer M, Drance SM, Douglas GR. A comparison of treated and untreated glaucoma suspects. *Ophthalmology* 1991;98:301–307. [PubMed: 2023749]
14. Fleming C, Whitlock EP, Beil T, Smit B, Harris RP. Screening for primary open-angle glaucoma in the primary care setting: an update for the US Preventive Services Task Force. *Ann Fam Med* 2005;3:167–170. [PubMed: 15798044]
15. American Academy of Ophthalmology. Preferred Practice Pattern for Primary Open-Angle Glaucoma. AAO; CA, USA: 2005.
16. Papadopoulos M, Khaw PT. Advances in the management of paediatric glaucoma. *Eye* 2007;21:1319–1325. [PubMed: 17914435]
17. Enyedi LB, Freedman SF. Latanoprost for the treatment of pediatric glaucoma. *Surv Ophthalmol* 2002;47:S129–S132. [PubMed: 12204709]
18. Shin J, Johnson JA. Pharmacogenetics of β -blockers. *Pharmacotherapy* 2007;27:874–887. [PubMed: 17542770]
19. Hoyn PF, van Beek LM. Pharmacological therapy for glaucoma: a review. *Drugs* 2000;59:411–434. [PubMed: 10776828]
20. Coakes RL, Brubaker RF. The mechanism of timolol in lowering intraocular pressure in the normal eye. *Arch Ophthalmol* 1978;96:2045–2048. [PubMed: 363105]
21. Zimmerman TJ, Harbin R, Pett M, Kaufman HE. Timolol and facility of outflow. *Invest Ophthalmol Vis Sci* 1977;16:623–624. [PubMed: 873723]
22. Sonntag JR, Brindley GO, Shields MB. Effect of timolol therapy on outflow facility. *Invest Ophthalmol Vis Sci* 1978;17:293–296. [PubMed: 627467]
23. Zimmerman TJ, Boger WP. The β -adrenergic blocking agents and the treatment of glaucoma. *Surv Ophthalmol* 1979;23:347–362. [PubMed: 37605]
24. Higginbotham EJ, Schuman JS, Goldberg I, et al. Bimatoprost study groups 1 and 2. One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. *Arch Ophthalmol* 2002;120:1286–1293. [PubMed: 12365906]

25. Netland PA, Landry T, Sullivan EK, et al. Travoprost Study Group. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. *Am J Ophthalmol* 2002;132:472–484. [PubMed: 11589866]
26. McLaren NC, Moroi SE. Clinical implications of pharmacogenetics for glaucoma therapeutics. *Pharmacogenomics J* 2003;3:197–201. [PubMed: 12931133]
27. Nieminen T, Lehtimäki T, Maenpää J, Ropo A, Uusitalo H, Kahonen M. Ophthalmic timolol: plasma concentration and systemic cardiopulmonary effects. *Scand J Clin Lab Invest* 2007;67:237–245. [PubMed: 17366003]
28. Leier CV, Baker ND, Weber PA. Cardiovascular effects of ophthalmic timolol. *Ann Intern Med* 1986;104:197–199. [PubMed: 3946944]
29. Nelson WL, Fraunfelder FT, Sills JM, Arrowsmith JB, Kuritsky JN. Adverse respiratory and cardiovascular events attributed to timolol ophthalmic solution, 1978–1985. *Am J Ophthalmol* 1986;15:606–611. [PubMed: 3777080]
30. McMahon CD, Shaffer RN, Hoskins HD, Hetherington J. Adverse effects experienced by patients taking timolol. *Am J Ophthalmol* 1979;88:736–738. [PubMed: 507146]
31. van Buskirk EM. Adverse reactions from timolol administration. *Ophthalmology* 1980;87:447–450. [PubMed: 7402590]
32. Bonomi L, Zavarise G, Noya E, Michieletto S. Effects of timolol maleate on tear flow in human eyes. *Albrecht Von Graefes Arch Klin Exp Ophthalmol* 1980;213:19–22. [PubMed: 6906142]
33. Fiscella RG, Green A, Patuszynski DH, Wilensky J. Medical therapy cost considerations for glaucoma. *Am J Ophthalmol* 2003;136:18–25. [PubMed: 12834665]
34. Stewart WC, Sine C, Cate E, Minno GE, Hunt H. Daily cost of β -adrenergic therapy. *Arch Ophthalmol* 1987;115:853–856. [PubMed: 9230824]
35. Sorensen SJ, Abel SR. Comparison of ocular β -blockers. *Ann Pharmacother* 1996;30:43–54. [PubMed: 8773166]
36. Eichelbaum M, Ingelman-Sundberg M, Evans WE. Pharmacogenomics and individualized drug therapy. *Annu Rev Med* 2006;57:119–137. [PubMed: 16409140]
37. Evans WE, Relling MV. Moving towards individualized medicine with pharmacogenomics. *Nature* 2004;429:464–468. [PubMed: 15164072]
38. Wax MB, Molinoff PB. Distribution and properties of β -adrenergic receptors in human iris–ciliary body. *Invest Ophthalmol Vis Sci* 1987;28:420–430. [PubMed: 3030954]
39. Taylor MRG. Pharmacogenetics of the human β -adrenergic receptors. *Pharmacogenomics J* 2007;7:29–37. [PubMed: 16636683]
40. Moore JD, Mason DA, Green SA, Hsu J, Liggett SB. Racial differences in the frequencies of cardiac $\beta(1)$ -adrenergic receptor polymorphisms: analysis of c145A>G and c1165G>C. *Hum Mutat* 1999;14:271. [PubMed: 10477438]
41. Mason DA, Moore JD, Green SA, Liggett SB. A gain-of-function polymorphism in a G-protein coupling domain of the human $\beta(1)$ -adrenergic receptor. *J Biol Chem* 1999;274:12670–12674. [PubMed: 10212248]
42. Levin MC, Marullo S, Muntaner O, Andersson B, Magnusson Y. The myocardium-protective Gly-49 variant of the $\beta(1)$ -adrenergic receptor exhibits constitutive activity and increased desensitization and down-regulation. *J Biol Chem* 2002;277:30429–30435. [PubMed: 12034720]
43. Green SA, Turki J, Innis M, Liggett SB. Amino-terminal polymorphisms of the human $\beta(2)$ -adrenergic receptor impart distinct agonist-promoted regulatory properties. *Biochemistry* 1994;33:9414–9419. [PubMed: 7915137]
44. Mialet Perez J, Rathz DA, Petrashevskaya NN, et al. $\beta(1)$ -adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. *Nat Med* 2003;9:1300–1305. [PubMed: 14502278]
45. Iwai C, Akita H, Kanazawa K, et al. Arg389Gly polymorphism of the human $\beta(1)$ -adrenergic receptor in patients with nonfatal acute myocardial infarction. *Am Heart J* 2003;146:106–109. [PubMed: 12851615]
46. Turki J, Pak J, Green SA, Martin RJ, Liggett SB. Genetic polymorphisms of the $\beta(2)$ -adrenergic receptor in nocturnal and nonnocturnal asthma. Evidence that Gly16 correlates with the nocturnal phenotype. *J Clin Invest* 1995;95:1635–1641. [PubMed: 7706471]

47. Timmermann B, Mo R, Luft FC, et al. β -2 adrenoceptor genetic variation is associated with genetic predisposition to essential hypertension: The Bergen Blood Pressure Study. *Kidney Int* 1998;53:1455–1460. [PubMed: 9607174]
48. Lanfear DE, Jones PG, Marsh S, Cresci S, McLeod HL, Spertus JA. β 2-adrenergic receptor genotype and survival among patients receiving β -blocker therapy after an acute coronary syndrome. *JAMA* 2005;294:1526–1533. [PubMed: 16189366]
49. del Moral R, Lopez ME, Nunez MI, et al. Interactions between radiotherapy and endocrine therapy in breast cancer. *Endocr Relat Cancer* 2002;9:197–205. [PubMed: 12237247]
50. Terra SG, McGorray SP, Wu R, et al. Association between β -adrenergic receptor polymorphisms and their G-protein-coupled receptors with body mass index and obesity in women: a report from the NHLBI-sponsored WISE study. *Int J Obes* 2005;29:746–754.
51. Miyaki K, Sutani S, Kikuchi H, et al. Increased risk of obesity resulting from the interaction between high energy intake and the Trp64Arg polymorphism of the β 3-adrenergic receptor gene in healthy Japanese men. *J Epidemiol* 2005;15:203–210. [PubMed: 16276029]
52. Hao K, Peng S, Xing H, et al. β (3) adrenergic receptor polymorphism and obesity-related phenotypes in hypertensive patients. *Obes Res* 2004;12:125–130. [PubMed: 14742851]
53. Schwartz SG, Puckett BJ, Allen RC, Castillo IG, Leffler CT. β 1-adrenergic receptor polymorphisms and clinical efficacy of betaxolol hydrochloride in normal volunteers. *Ophthalmology* 2005;112:2131–2136. [PubMed: 16325708]
54. Nieminen T, Uusitalo H, Maenpaa J, et al. Polymorphisms of genes *CYP2D6*, *ADRB1* and *GNAS1* in pharmacokinetics and systemic effects of ophthalmic timolol. A pilot study. *Eur J Clin Pharmacol* 2005;61:811–819. [PubMed: 16315032] • **One of the first studies to look at *CYP2D6* polymorphisms in glaucoma therapy.**
55. McCarty CA, Wilke RA, Giampietro PF, Wesbrook S, Caldwell MD. Marshfield Clinic Personalized Medicine Research Project (PMRP): design, methods and recruitment for a large, population-based biobank. *Personalized Medicine* 2005;2:49–79.
56. McCarty CA, Burmester JK, Mukesh BN, Patchett RB, Wilke RA. Pressure response to topical β -blockers is associated with an *ADRB2* SNP. *Arch Ophthalmol*. 2008In Press •• **Recent study quantifying the role of *ADRB* polymorphisms in glaucoma therapy.**
57. Inagaki Y, Mashima Y, Fuse N, et al. Polymorphism of β -adrenergic receptors and susceptibility to open-angle glaucoma. *Mol Vis* 2006;12:673–680. [PubMed: 16785856]
58. Gungor K, Beydagi H, Bekir N, et al. The impact of acute dynamic exercise on intraocular pressure: role of the β 2-adrenergic receptor polymorphism. *J Int Med Res* 2002;30:26–33. [PubMed: 11921496]
59. McLaren N, Reed DM, Musch DC, et al. Evaluation of the β 2-adrenergic receptor gene as a candidate glaucoma gene in 2 ancestral populations. *Arch Ophthalmol* 2007;125:105–111. [PubMed: 17210860]
60. Kirchheiner J, Heesch C, Bauer S, et al. Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics. *Clin Pharmacol Ther* 2004;76:302–312. [PubMed: 15470329]
61. Rau T, Heide R, Bergmann K, et al. Effect of the *CYP2D6* genotype on metoprolol metabolism persists during long-term treatment. *Pharmacogenetics* 2002;12:465–472. [PubMed: 12172215]
62. Edeki TI, He H, Wood AJ. Pharmacogenetic explanation for excessive β -blockade following timolol eye drops. Potential for oral–ophthalmic drug interaction. *JAMA* 1995;274:1611–1613. [PubMed: 7474246]
63. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. *Br J Ophthalmol* 2006;90:262–267.
64. Wilke RA, Reif DG, Moore JH. Combinatorial pharmacogenetics. *Nat Rev Drug Discov* 2005;4:911–918. [PubMed: 16264434]
65. Wilke RA, Mareedu R, Moore JH. The pathway less traveled: moving toward candidate genes and candidate pathways in the analysis of genome wide data from large-scale pharmacogenetic association studies. *Curr Pharmacogenomics Personalized Med*. 2008In Press • **An approach using pathway-based data to inform the analysis of genome scans.**


Websites

101. OMIM www.ncbi.nlm.nih.gov/sites/entrez?db=OMIM&itool=toolbar
102. SOURCE (unification tool) 2007 <http://smd.stanford.edu/cgi-bin/source/sourceSearch>
103. Home Page of the Human Cytochrome P450 (CYP) Allele Nomenclature Committee
www.imm.ki.se/CYPalleles/cyp2d6.htm



Modified from the National Eye Institute, NIH, USA.

Figure 1.
Human eye anatomy



The blue arrows depict aqueous humor secreted in the ciliary body outflowing through the pupil into the anterior chamber and draining into the bloodstream through the trabecular meshwork. Modified from the National Eye Institute, NIH, USA.

Figure 2. Anterior chamber Structures involved in aqueous humor production and outflow in the eye

Table 1

Current pharmacologic options for the treatment of glaucoma.

Drugs	Mechanism of action
β -adrenergic antagonists (β -blockers)	Decrease in aqueous humor production by blocking adrenergic β -receptors in the ciliary body
Prostaglandin analogs	Increase of aqueous humor uveoscleral outflow by decreasing the extracellular matrix in the ciliary body
α -adrenergic agonists	Both decrease of aqueous humor production and increase of aqueous humor outflow
Carbonic anhydrase inhibitors	Decrease of aqueous humor production by inhibition of carbonic anhydrase and decrease of bicarbonate production in the ciliary body
Cholinergic agonists	Increase of trabecular meshwork outflow by stimulating parasympathetic receptors at neuromuscular junctions

Table 2Common functional polymorphisms due to coding SNPs in the *ADRB* genes.

Gene	Identified polymorphisms	Clinical relevance	Associated with interindividual variability in IOP response to β -blockers	Ref.
<i>ADRB1</i>	Ser49Gly	Yes	Yes	[53]
	Arg389Gly	Yes	No	[54]
<i>ADRB2</i>	Arg16Gly	Yes	No	[56]
	Gln27Glu	Yes	Yes	[56]
<i>ADRB3</i>	Trp64Arg	Yes	No	[51]

IOP: Intraocular pressure.